articleTop 1% cited

Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer

Journal of Clinical Oncology · 2003 · Vol. 21(20) · pp. 3737–3743

Victor J. Verwaal✉(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital)Serge van Ruth(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital)Eelco de Bree(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital)Gooike W. van Slooten(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital)Harm van Tinteren(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital)Henk Boot(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital)F.A.N. Zoetmulder(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital)

View via DOI Publisher page

Abstract

Cytoreduction followed by HIPEC improves survival in patients with peritoneal carcinomatosis of colorectal origin. However, patients with involvement of six or more regions of the abdominal cavity, or grossly incomplete cytoreduction, had still a grave prognosis.

Intraperitoneal and Appendiceal Malignancies Appendicitis Diagnosis and Management Ovarian cancer diagnosis and treatmentMedicineHyperthermic intraperitoneal chemotherapyChemotherapySurgeryColorectal cancerLog-rank testCancerInternal medicineSurvival analysisGastroenterology

MeSH terms

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinomaCombined Modality TherapyFemaleHumansHyperthermia, InducedInjections, IntraperitonealMaleMiddle AgedPalliative CarePeritoneal NeoplasmsColorectal NeoplasmsTreatment Outcome

Citations

2,010

FWCI

39.39

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer